CEO Joel Lewis was paid $1,174,782 in fiscal year 2025, ↓ down 1.3% from fiscal year 2024 (SEC filing 0001140361-26-039379 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$1,174,782 ↓ Joel Lewis total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | 97.53% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
GALT's next annual pay disclosure, estimated October 4, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Joel Lewis | $624,000 | $312,000 | $182,763 | — | — | — | $56,019 | $1,174,782 |
| Chief Executive Officer & President | ||||||||
| Jack Callicutt | 400,000 | 220,000 | 130,545 | — | — | — | 56,019 | 806,564 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Joel Lewis | $1,174,782 | $1,189,674 | $963,647 | ↓ −14,892 |
| Jack Callicutt | 806,564 | 716,945 | 561,419 | ↑ +89,619 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Galectin Therapeutics's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper GALT reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses GALT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named GALT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Joel Lewis | CEO | $1,174,782 |
| Khurram Jamil, M.D. | Chief Medical Officer | $945,847 |
| Jack Callicutt | CFO | $806,564 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Benjamin S. Carson Sr., M.D | Director | $92,260 |
| Elissa J. Schwartz, Ph.D | Independent Director | $95,760 |
| Gilbert F. Amelio, Ph.D | Independent Director | $107,760 |
| Gilbert S. Omenn, M.D., Ph.D | Independent Director | $102,260 |
| Harold H. Shlevin, Ph.D | Independent Director | — |
| Kary Eldred | Independent Director | $99,760 |
| Kevin D. Freeman | Independent Director | $108,260 |
| Marc Rubin, M.D | Independent Director | $95,760 |
| Richard A. Zordani | Independent Director | $107,260 |
| Richard E. Uihlein | Independent Director | $92,260 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Joel Lewis | Option | 45,500 | 1.23 | — |
| Jack Callicutt | Option | 65,000 | 1.72 | — |
| Jack Callicutt | Option | 32,500 | 1.23 | — |
The Company provides a competitive total compensation package through a combination of base salary, annual performance bonuses, and long-term equity awards to attract, retain, and reward qualified executives. The program is designed to align executive interests with corporate success and stockholder interests by making a portion of compensation dependent upon performance and including long-term equity incentives.
| CEO STI target (% of salary) | 50% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Barney & Barney LLC |
| Clawback policy | True |
| Anti-hedging | False |
| Anti-pledging | false |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-12-03 | 25,260,489 | 639,415 | 310,420 | 97.53% | Passed |
| 2022 | 2022-12-01 | 16,271,959 | 1,450,200 | 428,140 | 91.82% | Passed |
| 2019 | 2019-12-04 | 20,584,969 | 2,767,101 | 557,416 | 88.15% | Passed |
| 2016 | 2016-12-15 | 10,263,034 | 844,997 | 142,823 | 92.39% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-12-03 | 97.53%a |
| 2022 | 2022-12-01 | 91.82%b |
| 2019 | 2019-12-04 | 88.15%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Kevin D. FreemanIndependent · Compensation · Audit · Nominating and Corporate Governance | $56,000 | $0 | $52,260 | $0 | $0 | $108,260 |
| Gilbert F. Amelio, Ph.DIndependent · Compensation · Nominating and Corporate Governance (Chair) | 55,500 | 0 | 52,260 | 0 | 0 | 107,760 |
| Richard A. ZordaniIndependent · Audit (Chair) | 55,000 | 0 | 52,260 | 0 | 0 | 107,260 |
| Gilbert S. Omenn, M.D., Ph.DIndependent · Compensation (Chair) | 50,000 | 0 | 52,260 | 0 | 0 | 102,260 |
| Kary EldredIndependent · Audit | 47,500 | 0 | 52,260 | 0 | 0 | 99,760 |
| Marc Rubin, M.DIndependent · Departed during FY | 43,500 | 0 | 52,260 | 0 | 0 | 95,760 |
| Elissa J. Schwartz, Ph.DIndependent · Nominating and Corporate Governance | 43,500 | 0 | 52,260 | 0 | 0 | 95,760 |
| Benjamin S. Carson Sr., M.DIndependent · Nominating and Corporate Governance | 40,000 | 0 | 52,260 | 0 | 0 | 92,260 |
| Richard E. UihleinIndependent · Board Chair | 0 | 40,000 | 52,260 | 0 | 0 | 92,260 |
| Harold H. ShlevinIndependent | 40,000 | 0 | 52,260 | 0 | 0 | 92,260 |
| Joel LewisEmployee director | — | — | — | — | — | 0 |
| Henry Brem, M.DNewly elected | — | — | — | — | — | — |
| Annual cash retainer | $35,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 5,000 / 3,500 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $431,000 |
| Equity awards (grant-date value) | $40,000 |
| All other compensation | $0 |
| Total cost of the board | $471,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Galectin Therapeutics | 2025 | Joel Lewis | $624,000 | $182,763 | — | — | $1,174,782 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Joel Lewis | DEF 14A | 2026-10-13 | 0001140361-26-039379 | Section “SUMMARY COMPENSATION TABLE” · page 29. As printed: 1,174,782. Filing ↗ |
| 2 | Section 01, Jack Callicutt | DEF 14A | 2026-10-13 | 0001140361-26-039379 | Section “SUMMARY COMPENSATION TABLE” · page 29. As printed: 806,564. Filing ↗ |
| 3 | Section 08, Kevin D. Freeman | DEF 14A | 2026-10-13 | 0001140361-26-039379 | Section “Director Compensation”. As printed: 108,260. Filing ↗machine: span 327443–327622 |
| 4 | Section 08, Gilbert F. Amelio, Ph.D | DEF 14A | 2026-10-13 | 0001140361-26-039379 | Section “Director Compensation”. As printed: 107,760. Filing ↗machine: span 317298–317477 |
| 5 | Section 08, Richard A. Zordani | DEF 14A | 2026-10-13 | 0001140361-26-039379 | Section “Director Compensation”. As printed: 107,260. Filing ↗machine: span 348093–348271 |
| 6 | Section 08, Gilbert S. Omenn, M.D., Ph.D | DEF 14A | 2026-10-13 | 0001140361-26-039379 | Section “Director Compensation”. As printed: 102,260. Filing ↗machine: span 331151–331330 |
| 7 | Section 08, Kary Eldred | DEF 14A | 2026-10-13 | 0001140361-26-039379 | Section “Director Compensation”. As printed: 99,760. Filing ↗machine: span 324222–324440 |
| 8 | Section 08, Marc Rubin, M.D | DEF 14A | 2026-10-13 | 0001140361-26-039379 | Section “Director Compensation”. As printed: 95,760. Filing ↗machine: span 334333–334551 |
| 9 | Section 08, Elissa J. Schwartz, Ph.D | DEF 14A | 2026-10-13 | 0001140361-26-039379 | Section “Director Compensation”. As printed: 95,760. Filing ↗machine: span 338076–338294 |
| 10 | Section 08, Benjamin S. Carson Sr., M.D | DEF 14A | 2026-10-13 | 0001140361-26-039379 | Section “Director Compensation”. As printed: 92,260. Filing ↗machine: span 320493–320711 |
| 11 | Section 08, Richard E. Uihlein | DEF 14A | 2026-10-13 | 0001140361-26-039379 | Section “Director Compensation”. As printed: 92,260. Filing ↗machine: span 345038–345256 |
| 12 | Section 08, Harold H. Shlevin | DEF 14A | 2026-10-13 | 0001140361-26-039379 | Section “Director Compensation”. As printed: 92,260. Filing ↗machine: span 341305–341523 |
| 13 | Section 08, Joel Lewis | DEF 14A | 2026-10-13 | 0001140361-26-039379 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 14 | Section 08, Henry Brem, M.D | DEF 14A | 2026-10-13 | 0001140361-26-039379 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 15 | Section 06, 2025 vote | Form 8-K | 2025-12-08 | 0001140361-25-044711 | Item 5.07 · say-on-pay result. As reported: 97.53% (votes for as printed: 25,260,489). Filing ↗ |
| 16 | Section 06, 2022 vote | Form 8-K | 2022-12-06 | 0001140361-22-044533 | Item 5.07 · say-on-pay result. As reported: 91.82% (votes for as printed: 16,271,959). Filing ↗ |
| 17 | Section 06, 2019 vote | Form 8-K | 2019-12-06 | 0001193125-19-307822 | Item 5.07 · say-on-pay result. As reported: 88.15% (votes for as printed: 20,584,969). Filing ↗ |
| 18 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 19 | Section 09b board cost (computed) | Computed | — | — | Cash 431,000 + equity 40,000 + all other 0 = 471,000, summed across the director compensation table rows.machine: formula: Σ = 471,000 |
| 20 | Galectin Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-10-13 | 0001140361-26-039379 | CEO total compensation as printed in Galectin Therapeutics's own proxy. As printed: 1,174,782. Filing ↗ |